The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.

The myelodysplastic syndromes (MDS) are disorders of the haematopoietic stem cells in the bone marrow, that result in a decreased production of blood cells. MDS mainly affects patients aged 70 and ...

A new study aims to investigate the feasibility and impact of multidisciplinary prehabilitation in adults with acute myeloid ...

What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient ...

Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable ...

With my myelodysplastic syndrome and age, I find it hard to keep up; however, cancer and fatigue have taught me to live at my ...

Aptadir Therapeutics, a biotech focused on RNA inhibitor therapies for cancer and genetic conditions, has launched with $1.6 ...

Stem cell transplant is a promising treatment option for patients with myelodysplastic syndrome (MDS). Still, the decision to ...

Italian biotech Aptadir Therapeutics has launched with the promise that its pipeline of preclinical RNA inhibitors could ...